Stock exchange release

Helsinki, Finland, 2011-12-28 12:02 CET (GLOBE NEWSWIRE) --

Communications procedure of Biohit Oyj on the publication of a press release on business sales

Biohit Oyj
Stock exchange release
28 December 2011 at 13:00 P.M.

NASDAQ OMX Helsinki issued today a public reprimand to Biohit Oyj concerning the publication of its company announcement from 26 October 2011on the sale of its Liquid Handling business. The service provider in charge of publishing Biohit Oyj’s stock exchange releases published the release on the Biohit news archive web pages before its release on the Biohit news page, which led to an unfortunate leak of information 49 minutes before the publication of the actual release.

This was a technical error on the part of the service provider and it will not happen again. In spite of this, Biohit Oyj will work to improve its information and follow-up processes to avoid the possibility of similar mistakes.

For further details, contact:

Osmo Suovaniemi
MD, PhD, Professor
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.fi

Distribution:

NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi

About Biohit

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission crystallises in its motto “Innovating for Health”. The company assumes social responsibility by producing innovations, new technologies and analysis systems for use in medicine, research institutions and industry. These products help to promote research and diagnostics, while improving quality of life by preventing disease, human suffering and financial loss. Biohit also seeks to innovate and develop the marketing and availability of its products and services, in order to ensure its profitable growth and ability to pay dividends.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations. These can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. (www.biohit.fi / International / State of the art GastroPanel and Acetium innovations for the unmet need)

Biohit's products include analysis systems for the prevention and early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach. (www.acetium.com/test - reveals acetaldehyde exposure)

Biohit employs around 35 people. The company is headquartered in Helsinki, Finland and has a subsidiary in the UK. Since 1999, Biohit’s Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV (www.biohit.fi).